Family · Pharmaceutical analytical standards
Venetoclax
A BH3-mimetic cancer medicine that blocks BCL-2, a protein that keeps leukaemia cells alive, pushing them towards programmed cell death: approved in 2016 in the United States and Europe, it is used for chronic lymphocytic leukaemia and acute myeloid leukaemia. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?It was the first approved medicine that works by blocking an interaction between proteins: it mimics the BH3 proteins, which normally bind to BCL-2 to start the cell's self-destruction.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
